WO2002043709A1 - Procede de production d'une preparation contenant une substance bioactive - Google Patents

Procede de production d'une preparation contenant une substance bioactive Download PDF

Info

Publication number
WO2002043709A1
WO2002043709A1 PCT/JP2001/010416 JP0110416W WO0243709A1 WO 2002043709 A1 WO2002043709 A1 WO 2002043709A1 JP 0110416 W JP0110416 W JP 0110416W WO 0243709 A1 WO0243709 A1 WO 0243709A1
Authority
WO
WIPO (PCT)
Prior art keywords
bioactive substance
preparation containing
containing bioactive
producing preparation
producing
Prior art date
Application number
PCT/JP2001/010416
Other languages
English (en)
French (fr)
Inventor
Yoshihiro Ohmachi
Masafumi Misaki
Shigeyuki Takada
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to DE60136958T priority Critical patent/DE60136958D1/de
Priority to EP01998183A priority patent/EP1346722B1/en
Priority to US10/433,156 priority patent/US7090869B2/en
Priority to AU2002224124A priority patent/AU2002224124A1/en
Priority to CA2430934A priority patent/CA2430934C/en
Publication of WO2002043709A1 publication Critical patent/WO2002043709A1/ja
Priority to US11/473,034 priority patent/US20060241045A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2001/010416 2000-12-01 2001-11-29 Procede de production d'une preparation contenant une substance bioactive WO2002043709A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60136958T DE60136958D1 (de) 2000-12-01 2001-11-29 Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
EP01998183A EP1346722B1 (en) 2000-12-01 2001-11-29 Method for producing preparation containing bioactive substance
US10/433,156 US7090869B2 (en) 2000-12-01 2001-11-29 Method for producing preparation containing bioactive substance
AU2002224124A AU2002224124A1 (en) 2000-12-01 2001-11-29 Method for producing preparation containing bioactive substance
CA2430934A CA2430934C (en) 2000-12-01 2001-11-29 A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
US11/473,034 US20060241045A1 (en) 2000-12-01 2006-06-23 Method for producing preparation containing bioactive substance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-367183 2000-12-01
JP2000367183 2000-12-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/473,034 Continuation US20060241045A1 (en) 2000-12-01 2006-06-23 Method for producing preparation containing bioactive substance

Publications (1)

Publication Number Publication Date
WO2002043709A1 true WO2002043709A1 (fr) 2002-06-06

Family

ID=18837665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010416 WO2002043709A1 (fr) 2000-12-01 2001-11-29 Procede de production d'une preparation contenant une substance bioactive

Country Status (8)

Country Link
US (2) US7090869B2 (ja)
EP (2) EP2062593A3 (ja)
JP (1) JP2009062389A (ja)
AT (1) ATE416784T1 (ja)
AU (1) AU2002224124A1 (ja)
CA (1) CA2430934C (ja)
DE (1) DE60136958D1 (ja)
WO (1) WO2002043709A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353856A1 (de) * 2003-11-18 2005-06-16 Goldschmidt Ag Emulgatorfreie Öl in Wasser-Emulsionen von Organopolysiloxanen und deren Verwendung in technischen Anwendungen
PT1586310E (pt) * 2004-04-15 2007-02-28 Helm Ag Processo para a preparação de adsorvatos de valsartan na forma de pó solto
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
WO2006009736A1 (en) * 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
BRPI0512261A (pt) 2004-06-17 2008-02-26 Wyeth Corp antagonistas de receptor de hormÈnio liberador de gonadotropina
EP1814866A2 (en) * 2004-11-23 2007-08-08 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
US7582634B2 (en) * 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US7531542B2 (en) * 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) * 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
US20070160672A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast films
US20070158880A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast tubes
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8207236B2 (en) * 2006-05-23 2012-06-26 Ferro Corporation Method for the production of porous particles
US20080166436A1 (en) * 2007-01-10 2008-07-10 Apperon Inc. Composition for normalizing otitis externa in mammals
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
US20090095164A1 (en) * 2007-05-17 2009-04-16 Salvatore Albert Celeste Method of enhancing beverages by means of a unique microencapsulated delivery system
US11039707B2 (en) * 2007-05-17 2021-06-22 International Flavors & Fragrances Inc. Microencapsulated delivery system
WO2008156356A1 (en) * 2007-06-19 2008-12-24 Feyecon Development & Implementation B.V. Preparation of a pharmaceutically active ingredient comprising a desolventising step
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
GB0907251D0 (en) * 2009-04-28 2009-06-10 Univ Leiden Coplymers
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MA33910B1 (fr) * 2009-12-22 2013-01-02 Takeda Pharmaceutcal Company Ltd Formulation à libération prolongée
JP2012184364A (ja) * 2011-03-07 2012-09-27 Seiko Instruments Inc アクリル樹脂およびその製造方法
AU2011377134B2 (en) 2011-09-18 2017-10-05 Bio Plasmar Ltd Bio-degradable compositions and use thereof
JP6068787B2 (ja) * 2011-09-30 2017-01-25 大王製紙株式会社 ティシュペーパーの製造方法
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
EP2727584A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Vent gases for use in drying, storing and/or reconstituting biomolecules
BR112015011583B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
JP2017190424A (ja) * 2016-04-15 2017-10-19 竹本油脂株式会社 ビニル共重合体
KR102281963B1 (ko) * 2016-04-27 2021-07-26 주식회사 쿠라레 아크릴계 열가소성 수지 조성물, 성형체, 필름과 그 제조 방법, 및 적층체
TW201808988A (zh) 2016-07-11 2018-03-16 歐科生物製品有限公司 長效型凝血因子及其生產方法
FR3068977B1 (fr) * 2017-07-12 2020-09-04 Arkema France Composition comprenant un polymere a phases multiples et un polymere (meth)acrylique, son procede de preparation et son utilisation
EP3502180A1 (en) * 2017-12-19 2019-06-26 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus
JPWO2020100791A1 (ja) * 2018-11-15 2021-09-27 三菱ケミカル株式会社 導電性組成物及びその製造方法と、導電体及びその製造方法
EP3950749A4 (en) * 2019-03-28 2022-12-21 Kaneka Corporation GRANULAR BODY AND ITS USE

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6128521A (ja) 1984-07-06 1986-02-08 Wako Pure Chem Ind Ltd 新規重合体及びその製造法
EP0421577A2 (en) 1989-07-10 1991-04-10 Syntex (U.S.A.) Inc. Solvent extraction process
EP0425921A1 (en) 1989-10-24 1991-05-08 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0459136A1 (en) 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0520423A2 (en) 1991-06-27 1992-12-30 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use as angiotensin II antagonists
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
EP0553879A2 (en) 1992-01-31 1993-08-04 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
EP0578125A1 (en) 1992-07-06 1994-01-12 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
EP0601799A1 (en) 1992-12-07 1994-06-15 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0668272A2 (en) 1994-01-28 1995-08-23 Takeda Chemical Industries, Ltd. A process for the production of tetrazolyl compounds
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
JPH08217691A (ja) 1994-09-09 1996-08-27 Takeda Chem Ind Ltd 徐放性製剤
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
EP0761213A2 (en) 1995-09-04 1997-03-12 Takeda Chemical Industries, Ltd. Method of production of sustained-release preparation
JPH09132524A (ja) 1995-09-04 1997-05-20 Takeda Chem Ind Ltd 徐放性製剤の製造法
US5766637A (en) 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
JPH10231252A (ja) 1996-12-20 1998-09-02 Takeda Chem Ind Ltd 徐放性製剤の製造法
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS528375B2 (ja) 1973-07-02 1977-03-09
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP0305387B2 (en) 1986-05-05 1996-08-28 The General Hospital Corporation Insulinotropic hormone
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
JP2861267B2 (ja) 1989-06-01 1999-02-24 萬有製薬株式会社 生理活性物質ｂｅ―１８２５７類
ES2071804T3 (es) * 1989-07-31 1995-07-01 Ciba Geigy Ag Extraccion de disolventes organicos de articulos conformados mediante fluidos supercriticos y gases casi criticos.
GB8919726D0 (en) 1989-08-31 1989-10-11 Fujisawa Pharmaceutical Co Ws7338 substances and preparation thereof
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
JPH0680584A (ja) 1992-07-13 1994-03-22 Nisshin Flour Milling Co Ltd グリセンチンを有効成分とする医薬
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
JPH07101877A (ja) 1993-10-04 1995-04-18 Mitsui Toatsu Chem Inc 血小板減少症治療剤
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
CA2178592C (en) * 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
WO1996020005A1 (en) 1994-12-23 1996-07-04 Novo Nordisk A/S Protracted glp-1 compositions
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH10265404A (ja) 1996-02-02 1998-10-06 Mitsui Chem Inc ヒト成長ホルモンを含有する医薬製剤
DE69717092T2 (de) 1996-03-01 2003-07-24 Novo Nordisk As Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP4758525B2 (ja) 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
CA2270320A1 (en) 1998-04-28 1999-10-28 Patricia Lee Brubaker Novel microsphere composition
NZ508823A (en) 1998-06-12 2003-10-31 Amylin Pharmaceuticals Inc Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance or increased risk of a cardiovascular or cerebrovascular event
JP4624558B2 (ja) 1998-08-10 2011-02-02 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6403672B1 (en) * 1998-11-30 2002-06-11 University Technology Corporation Preparation and use of photopolymerized microparticles
PL208751B1 (pl) 1998-12-07 2011-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
KR100452417B1 (ko) 1998-12-07 2004-10-12 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
CN100356978C (zh) 1999-01-14 2007-12-26 安米林药品公司 新型exendin激动剂制剂及其给药方法
AU775063C (en) 1999-04-30 2005-05-12 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
AU2002345758A1 (en) * 2001-06-22 2003-01-08 Raveendran Poovathinthodiyil Renewable, carbohydrate based co2-philes

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6128521A (ja) 1984-07-06 1986-02-08 Wako Pure Chem Ind Ltd 新規重合体及びその製造法
EP0421577A2 (en) 1989-07-10 1991-04-10 Syntex (U.S.A.) Inc. Solvent extraction process
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
EP0425921A1 (en) 1989-10-24 1991-05-08 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0459136A1 (en) 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0520423A2 (en) 1991-06-27 1992-12-30 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use as angiotensin II antagonists
EP0553879A2 (en) 1992-01-31 1993-08-04 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
EP0578125A1 (en) 1992-07-06 1994-01-12 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
EP0601799A1 (en) 1992-12-07 1994-06-15 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0668272A2 (en) 1994-01-28 1995-08-23 Takeda Chemical Industries, Ltd. A process for the production of tetrazolyl compounds
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
JPH08217691A (ja) 1994-09-09 1996-08-27 Takeda Chem Ind Ltd 徐放性製剤
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
EP0761213A2 (en) 1995-09-04 1997-03-12 Takeda Chemical Industries, Ltd. Method of production of sustained-release preparation
JPH09132524A (ja) 1995-09-04 1997-05-20 Takeda Chem Ind Ltd 徐放性製剤の製造法
US5766637A (en) 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
JPH10231252A (ja) 1996-12-20 1998-09-02 Takeda Chem Ind Ltd 徐放性製剤の製造法
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"A guideline for residual solvent in medicament", PHARM. TECH. JAPAN, vol. 16, no. 5, 2000, pages 687 - 704

Also Published As

Publication number Publication date
US20060241045A1 (en) 2006-10-26
ATE416784T1 (de) 2008-12-15
US20040018240A1 (en) 2004-01-29
EP2062593A2 (en) 2009-05-27
JP2009062389A (ja) 2009-03-26
AU2002224124A1 (en) 2002-06-11
DE60136958D1 (de) 2009-01-22
CA2430934A1 (en) 2002-06-06
US7090869B2 (en) 2006-08-15
EP1346722B1 (en) 2008-12-10
EP1346722A4 (en) 2005-08-03
EP2062593A3 (en) 2011-08-17
EP1346722A1 (en) 2003-09-24
CA2430934C (en) 2011-06-21

Similar Documents

Publication Publication Date Title
WO2002043709A1 (fr) Procede de production d'une preparation contenant une substance bioactive
WO2006079709A3 (fr) Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
WO2004026182A3 (en) Method and apparatus for loading a beneficial agent into an expandable medical device
ATE330586T1 (de) Pharmazeutische tablette und eine verfahren zu deren herstellung
WO2004035020A3 (en) Controlled release preparation
WO2005048923A3 (en) Extended release venlafaxine formulation
WO2003034940A3 (en) Balloon expandable polymeric stent with reduced elastic recoil
AU2001270588A1 (en) Method for producing capsules containing an active ingredient and having an ultra-thin coating
WO2003005951A3 (en) Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
WO2005025840A3 (en) Methods for the manufacture of porous prosthesis
DE69936430D1 (de) Verfahren zur Herstellung von in der Mundhöhle rasch zerfallenden Tabletten
WO2003002251A3 (en) Process for preparing fluorination catalyst
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
WO2006058675A3 (de) Modifizierte offenzellige schaumstoffe und verfahren zu ihrer herstellung
WO2004032644A3 (en) Chewing gum formulation and method of making the same
WO2002038129A3 (en) Delayed-release pharmaceutical formulations containing proinsulin c-peptide
WO2007144169A3 (en) Entacapone-derivatives
MXPA03011966A (es) Metodo y dispositivo para producir tabletas revestidas por compresion.
WO2004028504A8 (en) Modified release dosage forms
DE3884214D1 (de) Verfahren zur herstellung einer festen form mit beibehaltender freisetzung aus einer funktionellen aktiven komposition und die bei dem verfahren erhaltene dosierungsform.
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
EP1552913A4 (en) METHOD FOR PRODUCING A CERAMIC FORMK RPTER
EP1300363A3 (en) Method for producing fullerenes
WO2003059329A3 (en) Polytartrate composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001998183

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2430934

Country of ref document: CA

Ref document number: 10433156

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001998183

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642